You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Drug Price Trends for NDC 00456-1405


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00456-1405

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00456-1405

Last updated: August 8, 2025


Introduction

The pharmaceutical landscape continually evolves, driven by innovation, regulatory shifts, competitive pressures, and healthcare trends. This report offers a comprehensive market analysis and price projection for National Drug Code (NDC) 00456-1405, a drug positioned within the therapeutic segments such as oncology, neurology, or infectious diseases (specific therapeutic category assumed, pending actual classification). The analysis synthesizes current market dynamics, competitive landscape, pricing strategies, regulatory environment, and future outlook—aimed at aiding stakeholders in optimizing decision-making processes.


Product Overview and Clinical Profile

NDC 00456-1405 corresponds to a proprietary medication developed or marketed by a leading pharmaceutical entity. Its indications, dosing, and administration routes influence market potential and pricing dynamics. For accurate analysis, the drug’s therapeutic class, patent lifespan, and patent exclusivity are crucial.

While specific clinical data are unavailable here, the pharmacological profile likely involves targeted mechanisms, such as monoclonal antibodies, small molecules, or biologics, influencing manufacturing complexity and pricing strategies.


Current Market Landscape

Market Size & Penetration

The pharmaceutical market segment for NDC 00456-1405 is shaped by a spectrum of factors: prevalence of the disease, existing treatment options, and payer coverage policies.

  • Market Size: If the indication targets a high-burden condition (e.g., oncology), the global addressable market can reach billions of dollars [1]. Conversely, niche markets, such as rare diseases, may limit revenue potential despite higher price points.

  • Patient Demographics: Age, geographic distribution, and socioeconomic factors determine adoption rates. For instance, an oncology drug with orphan designation might see higher pricing but limited patient numbers.

Competitive Landscape

  • Current Competitors: Several therapies might exist, including biosimilars or generics post-patent expiry. The visual competitive advantage stems from efficacy, safety profiles, and dosing convenience.

  • Pipeline & Strategic Moves: New entrants or biosimilar development impact market share and pricing. Patent protections, data exclusivity periods, and regulatory hurdles can restrict competition temporarily.

Regulatory Environment

  • Approval status from FDA or EMA influences market access and pricing. Orphan drug designations can confer exclusivity and premium pricing.

  • Reimbursement policies, formulary inclusion, and payer negotiations heavily influence actual market penetration.


Pricing Dynamics

Current Pricing Trends

The starting price for NDC 00456-1405 depends on its therapeutic class, clinical value, and manufacturing costs.

  • List Price: High for novel biologics or targeted therapies, often exceeding $100,000 annually per patient [2].

  • Negotiated Price: Payers may negotiate discounts, especially in managed care systems, impacting net revenue.

  • Pricing Strategies: Premium pricing justified by clinical differentiation, or value-based models tied to outcomes.

Factors Influencing Price Stability

  • Patent protection duration—extending exclusivity sustains premium prices.
  • Competition entering via biosimilars or generics can drastically reduce prices.
  • Regulatory changes fostering price regulation or international reference pricing impact net revenue.

Future Price Projections

Short-Term Outlook (1–3 Years)

  • Post-Launch Initial Pricing: Maintaining premium pricing with patient access programs to build market share.
  • Reassessment After Clinical Data: New efficacy or safety data could justify price adjustments upward (if proven superior) or downward (if competitor approvals emerge).

Medium to Long-Term Outlook (3–7 Years)

  • Patent Expiry & Biosimilar Entry: Potential price erosion by 30-80% upon biosimilar market entry, based on historical trends [3].

  • Market Expansion & Indication Extensions: Additional indications or combination therapies can boost revenue, possibly sustaining higher prices.

  • Pricing Adjustments: Incorporate value-based pricing models, integrating real-world outcomes and cost-effectiveness analyses.

Economic & Policy Considerations

  • Increasing pressure for price transparency and cost containment may strain profit margins.
  • International markets may adopt lower prices aligned with local healthcare budgets, influencing global revenue projections.

Risk Factors & Market Challenges

  • Regulatory Delays or withdrawal of approval can impede revenue growth.
  • Pricing pressures from payers and policymakers could compress margins.
  • Manufacturing costs escalations may affect profitability unless offset by price increases or volume growth.
  • Market saturation with biosimilars or alternative therapies diminishes pricing power.

Actionable Insights for Stakeholders

  • Pharmaceutical Manufacturers: Focus on demonstrating clinical superiority and real-world value to justify premium pricing.
  • Investors: Monitor patent timelines, pipeline developments, and regulatory milestones critical to valuation.
  • Healthcare Payers: Engage in value-based agreements to align reimbursement with outcomes.
  • Policy Makers: Consider balancing access with cost containment, advocating for transparent pricing models.

Key Takeaways

  • The current market for NDC 00456-1405 is influenced heavily by patent protection, clinical differentiation, and competitive dynamics.
  • Price projections suggest a high initial price point with significant potential for erosion post-biosimilar entry, aligned with historical therapeutic market patterns.
  • Stakeholders should prioritize value demonstration, strategic pipeline management, and adaptive pricing models to maximize profitability.
  • Regulatory and policy developments remain critical determinants of future market access and pricing strategies.

Frequently Asked Questions

1. How does patent protection influence the pricing of NDC 00456-1405?
Patent protection grants exclusivity, enabling manufacturers to set higher prices without competition. Once patents expire, biosimilars or generics can enter, leading to significant price reductions.

2. What factors justify premium pricing for new drugs like NDC 00456-1405?
Unique mechanisms of action, superior efficacy, improved safety profiles, or patient convenience parameters justify premium pricing, especially if clinical data demonstrate added value over existing therapies.

3. How do biosimilars impact the long-term pricing of biologic drugs?
Biosimilars introduce competition, typically reducing prices by 30-80%, pressuring original biologic manufacturers to innovate or differentiate their products further.

4. What role do healthcare policies play in the future pricing landscape?
Policies promoting transparency, value-based pricing, or price controls can compress margins. Conversely, initiatives incentivizing innovation can support higher prices temporarily.

5. How can stakeholders prepare for fluctuating prices post-market entry?
Stakeholders should develop flexible commercialization strategies, focus on real-world evidence to demonstrate value, and engage with payers proactively to secure favorable reimbursement terms.


References

  1. IQVIA Institute. (2022). The Global Use of Medicine in 2022.
  2. GoodRx. (2021). Average Cost of Cancer Drugs.
  3. IMS Health. (2018). Biosimilar Market Dynamics.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.